Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 15/20 | 0.38 |
| ▸ | CDK9 | P50750 | 15/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623959 | 0.81 | ALDH1A1 (0.33) | KDM4EALDH1A1NPSR1KCNH2 | |
| SCHEMBL577888 | 0.80 | TSHR (0.40) | KDM4EALDH1A1NPSR1KCNH2 | |
| SCHEMBL13998879 | 0.70 | CCNT1 (0.43) | CCNT1CDK9 | |
| SCHEMBL24922409 | 0.70 | RAB9A (0.38) | CCNT1CDK9KDM4EALDH1A1 | |
| SCHEMBL575444 | 0.70 | TSHR (0.50) | — | |
| SCHEMBL577670 | 0.68 | MEN1 (0.42) | KDM4EALDH1A1NPSR1KCNH2 | |
| SCHEMBL23119310 | 0.68 | STIM1 (0.37) | KDM4EALDH1A1KCNH2 | |
| SCHEMBL5484510 | 0.66 | TSHR (0.48) | — | |
| SCHEMBL5795783 | 0.66 | RIPK1 (0.38) | KDM4EALDH1A1NPSR1KCNH2 | |
| SCHEMBL8347665 | 0.66 | CETP (0.49) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291921-A1 | INTEGRASE INHIBITORS | TYMP, DNTT, PAICS | CCNT1 407/4885CDK9 27/4885KDM4E 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.